Krebs Biochemicals to Merge with Ipca Laboratories

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take place under Sections 230-232 of the Companies Act, 2013. The appointed date for the scheme is April 1, 2026. The rationale includes achieving operational synergies, cost optimization, consolidation of business, and leveraging Krebs' fermentation-based API manufacturing capabilities. Ipca Laboratories reported a standalone audited total income of ₹7431 Crores for FY26, while Krebs Biochemicals had an income of ₹26 Crores, primarily from conversion charges. The transaction is considered a related party transaction but will be conducted at arm's length. There will be no cash consideration; instead, Ipca Laboratories will issue 7 equity shares for every 200 shares of Krebs Biochemicals.